Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
PALI
Palisade Bio, Inc.
Lead asset PALI-2108 targets immunology/inflammatory diseases (IBD), aligning with Immunology Therapeutics.
|
$357.61M |
$2.40
+2.79%
|
|
DMAC
DiaMedica Therapeutics Inc.
DMAC's lead DM199 is a peptide/protein-based therapeutic (recombinant KLK1) aimed at treating AIS and PE.
|
$356.73M |
$6.86
+3.55%
|
|
KROS
Keros Therapeutics, Inc.
Duchenne muscular dystrophy (DMD) and associated cytopenias are rare diseases, aligning Keros Therapeutics' focused assets to Rare Diseases.
|
$355.54M |
$11.68
-0.34%
|
|
SLN
Silence Therapeutics plc
Silence Therapeutics directly develops RNA interference therapeutics (siRNA) as its core product modality.
|
$355.32M |
$7.53
-0.92%
|
|
CADL
Candel Therapeutics, Inc.
CAN-2409 and CAN-3110 are viral vector-based therapies, aligning with gene therapy.
|
$349.70M |
$6.38
+23.64%
|
|
TOI
The Oncology Institute, Inc.
Radiopharmaceutical therapy is a modality offered in their oncology practice.
|
$348.27M |
$3.54
-0.14%
|
|
IMMX
Immix Biopharma, Inc.
Directly categorizes the company’s lead product as a CAR-T cell therapy (cell therapy).
|
$347.53M |
$10.35
+3.87%
|
|
SIGA
SIGA Technologies, Inc.
SIGA's core product is TPOXX, a small-molecule antiviral for orthopoxviruses, directly produced and marketed by the company.
|
$340.87M |
$4.75
+2.26%
|
|
EDIT
Editas Medicine, Inc.
Core product category: in vivo gene therapy using Editas's gene-editing platform (AsCas12a) delivered via targeted lipid nanoparticles (tLNP).
|
$340.69M |
$3.49
+4.18%
|
|
ZNTL
Zentalis Pharmaceuticals, Inc.
Zentalis is a biotech company focused on oncology therapies, centered on cancer indications with their lead asset azenosertib.
|
$335.24M |
$4.62
-7.97%
|
|
CLPT
ClearPoint Neuro, Inc.
SmartFlow cannula represents a drug-delivery platform for targeted brain infusion, tied to cell/gene therapy delivery approaches.
|
$335.11M |
$11.79
+12.29%
|
|
CABA
Cabaletta Bio, Inc.
Core product category: CAR-T cell therapy platform (CARTA) and rese-cel directly produced by Cabaletta.
|
$331.15M |
$3.43
-2.56%
|
|
AVXL
Anavex Life Sciences Corp.
Company's lead product and pipeline consist of oral small-molecule therapeutics (ANAVEX 2-73 and ANAVEX 3-71).
|
$325.23M |
$3.63
+6.91%
|
|
RZLT
Rezolute, Inc.
Ersodetug is a human monoclonal antibody designed to treat HI by modulating insulin signaling, representing a monoclonal antibody therapeutic product.
|
$320.84M |
$3.45
-2.54%
|
|
CLLS
Cellectis S.A.
Lead assets UCART22 and UCART20x22 are allogeneic cell therapies (CAR-T) directly developed and manufactured by the company.
|
$319.68M |
$4.45
+4.22%
|
|
ORGO
Organogenesis Holdings Inc.
ReNu knee osteoarthritis program is a cell therapy (biotech) product, aligning with Biotech - Cell Therapy.
|
$317.28M |
$2.50
-1.96%
|
|
CATX
Perspective Therapeutics, Inc.
Company directly develops and provides radiopharmaceuticals using alpha-emitting Lead-212 for targeted cancer therapy and diagnostic imaging via 203Pb in a theranostic approach.
|
$312.22M |
$4.24
-0.59%
|
|
ARTV
Artiva Biotherapeutics, Inc.
AlloNK AB-101 is an allogeneic NK cell therapy platform, constituting Artiva's core product line.
|
$308.04M |
$12.50
+3.22%
|
|
AMRN
Amarin Corporation plc
Amarin's flagship product VASCEPA/icosapent ethyl is a cardiovascular drug indicated to reduce major adverse cardiovascular events when added to statin therapy, making 'Cardiovascular Drugs' a core category.
|
$304.32M |
$14.91
+1.29%
|
|
EOLS
Evolus, Inc.
Evolus directly produces botulinum toxin type A product (Jeuveau) used for cosmetic neuromodulation, a core injectable aesthetic treatment.
|
$304.00M |
$4.68
+3.42%
|
|
ACIU
AC Immune S.A.
Alzheimer's Disease Therapeutics – the company focuses on active immunotherapies and diagnostic assets for Alzheimer's disease.
|
$303.69M |
$3.00
-2.12%
|
|
SCPH
scPharmaceuticals Inc.
FUROSCIX is a cardiovascular drug (diuretic) approved for heart failure and CKD, representing SCPH's core product.
|
$299.33M |
$5.67
|
|
FHTX
Foghorn Therapeutics Inc.
Clinical-stage biotech focused on oncology therapies targeting chromatin regulatory system (SMARCA2/BRG1, CBP/EP300, ARID1B degraders), a cancer-focused platform.
|
$299.16M |
$5.29
+8.95%
|
|
ABEO
Abeona Therapeutics Inc.
ZEVASKYN is an autologous cell-based therapy (cell therapy) targeting RDEB wounds.
|
$298.05M |
$5.52
+2.60%
|
|
CBIO
Crescent Biopharma, Inc.
Crescent Biopharma focuses on oncology therapeutics, explicitly mentioning next-gen cancer biologics and its lead PD-1 x VEGF bispecific and ADCs.
|
$295.63M |
$21.20
+9.00%
|
|
IVVD
Invivyd, Inc.
Invivyd's PEMGARDA and pipeline candidate VYD2311 are monoclonal antibody therapeutics targeting evolving viral threats, making Monoclonal Antibody Therapeutics the core product category.
|
$285.94M |
$2.29
-3.99%
|
|
CCCC
C4 Therapeutics, Inc.
Lead assets (e.g., cemsidomide) are orally bioavailable small-molecule degraders, fitting the 'Oral Small Molecule Therapeutics' category.
|
$282.99M |
$2.92
+0.69%
|
|
ALEC
Alector, Inc.
Latozinemab and AL101 are monoclonal antibody therapeutics in the pipeline.
|
$280.52M |
$2.57
+0.78%
|
|
PRLD
Prelude Therapeutics Incorporated
Prelude is a clinical-stage biotech focused on oncology, with an advanced pipeline targeting SMARCA2/SMARCA4 and related cancer pathways.
|
$279.12M |
$4.46
+0.56%
|
|
ACHV
Achieve Life Sciences, Inc.
Cytisinicline is an oral small-molecule therapeutic candidate for smoking cessation, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$271.49M |
$5.11
+6.13%
|
|
SRZN
Surrozen, Inc.
Direct ophthalmic drug development focusing on retinal diseases using Wnt-modulating antibodies.
|
$270.51M |
$31.62
+4.29%
|
Showing page 13 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
